Mark C. Schneyer Sells 2,708 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark C. Schneyer sold 2,708 shares of the business's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total value of $40,132.56. Following the completion of the transaction, the executive vice president now directly owns 59,456 shares in the company, valued at $881,137.92. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.47 during mid-day trading on Friday, hitting $14.58. 1,904,307 shares of the stock were exchanged, compared to its average volume of 1,856,316. The company has a 50-day simple moving average of $17.57 and a 200 day simple moving average of $16.97. The company has a market capitalization of $2.43 billion, a P/E ratio of 18.69 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $20.68.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently made changes to their positions in ACAD. Virtus Fund Advisers LLC bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at about $39,000. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at approximately $47,000. GF Fund Management CO. LTD. bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at approximately $64,000. KBC Group NV increased its stake in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 2,044 shares during the last quarter. Finally, Globeflex Capital L P bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $168,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ACAD shares. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price on the stock. Guggenheim cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. StockNews.com raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Morgan Stanley restated an "equal weight" rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $23.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.